PatientsVille.com Logo


Prednison Medical Research Studies

Up-to-date List of Prednison Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Prednison Medical Research Studies

Rank Status Study
1 Recruiting Clinical Trial Treatment in Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: cyclosporine +mycophenolic acid+Prednison;   Drug: Mycophenolic Acid + Prednison
Outcome Measures: Complete remission: - Proteinuria < 0.3 g/24h - Albumin normal - eGFR > 60 mL/min/1.73 m2;   Partial remission: Proteinuria 0.3-3.5 g/24 hours, with a decrease > 50% over basal, stable renal function and albumin normal;   To Analyze the safety and tolerance in the two groups;   To Compare the development of proteinuria in two groups;   To compare the renal evolution in two groups
2 Recruiting Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide, endoxan, Prednisone;   Drug: lenalidomide, endoxan, Prednisone
Outcome Measures: Phase 1 Revlimid, Endoxan, Prednisone Evaluation After prior revlimid Treatment (REPEAT);   phase 1 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT);   phase 2 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT)
3 Unknown  The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease
Conditions: Cat-scratch Disease;   Bartonella Infections
Interventions: Drug: Prednison and azithromycin;   Drug: Prednison, azithromycin;   Drug: Prednison, Azenil
Outcome Measure: Severity score of lymphadenitis using a lymphadenitis Score (LS).
4 Recruiting Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus
Condition: Liver Disease
Interventions: Drug: Tacrolimus and Sirolimus;   Drug: Tacrolimus
Outcome Measures: Renal function;   Malignancies;   de novo Diabetes Mellitus
5 Recruiting Alemtuzumab and CHOP in T-cell Lymphoma
Condition: Lymphoma, T-Cell, Peripheral
Interventions: Drug: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, Prednison) plus G-CSF, combined with alemtuzumab;   Drug: CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
Outcome Measures: Event-free Survival;   Overall survival;   Overall response rate;   Overall response rate related to the CD52 expression;   Tumor control or time-to-progression;   Safety measured as number of adverse events (AEs) and serious adverse events (SAEs);   Feasibility of successful stem cell harvest i.e. >/=2E6 CD34 positive cells
6 Recruiting Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Prednisone;   Drug: Placebo
Outcome Measures: Expanded Disability Status Scale (EDSS);   Multiple Sclerosis Functional Composite Score (MSFC);   Gd-enhancing lesions on T1-weighted images;   number of new T2-hyperintense lesions;   mental status (MUSIC);   Euroqol-5D (EQ-5D;   Functional Assessment Multiple Sclerosis (FAMS);   Beck Depression Inventory Second edition (BDI-II);   Fatigue Scale for Motor and Cognitive functions (FSMC)
7 Unknown  A Proof of Concept Study to Determine the Local Delivery and Efficacy of Nanocort
Condition: Atherosclerosis
Interventions: Drug: Nanocort;   Drug: Methylprednisolone;   Drug: Placebo
Outcome Measures: Quantity of PEG liposomes in the atherosclerotic plaque and/ or in atherosclerotic macrophages as determined with a PEG antibody quantitative sandwich ELISA.;   Differences between TNF-alpha levels in the supernatant of isolated macrophages from the atherosclerotic tissue as determined by quantitative sandwich ELISA;   Concentration of corticosteroids in plaque.
8 Recruiting Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Valproate;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
Outcome Measure: Establishment of maximum tolerable dose of valproate.
9 Recruiting CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis
Condition: Primary Disease
Intervention: Drug: liposomal cytarabine
Outcome Measures: Time to treatment failure;   Maximal hematological, gastrointestinal, neuronal and other toxicities;   Clinical response rate;   Incidence of central nervous system(CNS) relapse in cerebrospinal fluid (CSF )cytology neg/flow cytometry positive cases;   Incidence of CNS relapse in a subgroup of patients with more than one extranodal site and elevated lactate dehydrogenase (LDH);   Progression free survival;   Overall survival;   Molecular predictors;   CNS relapse rate
10 Recruiting Treatment Optimization in Patients With Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Placebo
Outcome Measures: Median Progression free survival;   overall survival;   sequence progression-free survival;   efficacy parameters according to the international uniform response criteria;   number and indication of adverse events;   Quality of life;   Time to treatment failure;   sequence overall survival
11 Recruiting Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)
Outcome Measures: progression-free survival (PFS);   event-free survival (EFS)
12 Recruiting Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy
Condition: Hyperglycemia Steroid-induced
Interventions: Drug: Sliding scale insulin;   Drug: Intermediate acting insulin;   Behavioral: Dietary advice;   Drug: Glucose lowering medication;   Drug: Chemotherapy
Outcome Measures: Glycemic control;   Patient satisfaction;   Clinical outcomes;   Hypoglycemia
13 Not yet recruiting Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy
Condition: Posttransplant Lymphoproliferative Disorder
Interventions: Drug: Rituximab sc;   Drug: Rituximab sc consolidation;   Drug: Rituximab sc combined with CHOP chemotherapy;   Drug: Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx
Outcome Measures: Event free survival (EFS) of low-risk patients in the intention to treat population with following definitions for low-risk and event:;   Overall survival;   Time to progression;   Progression-free survival;   Response at interim staging;   Response after full treatment;   Duration of response;   Treatment-related mortality

These studies may lead to new treatments and are adding insight into Prednison etiology and treatment.

A major focus of Prednison research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Prednison